Scheduled Events

Oral Presentations

Session title: Enzalutamide​​​​​​​
Description: Enzalutamide in metastatic hormone-sensitive prostate cancer patients who received prior antiandrogen therapy: post hoc analysis of ARCHES
Abstract No: PD34-07​​​​​​​
Session Date and Time:
09/11/2021, 4:30PM-4:40PM PDT

Session title: Avelumab​​​​​​​​​​​​​​
Description: Avelumab first-line maintenance for advanced urothelial carcinoma in the JAVELINBladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance​​​​​​​
Abstract No: PD55-01
Session Date and Time:
09/13/2021, 7:00AM - 7:10AM PDT

Pfizer Posters

Session title: Relugolix
Description: Relugolix vs leuprolide effects on castration resistance-free survival from the phase 3 HERO study in men with advanced prostate cancer
Abstract No: MP24-07
Session Date and Time:
09/11/2021, 8:45AM-10:00AM PDT

Session title: Avelumab
Description: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line therapy in JAVELIN Bladder 100
Abstract No: MP41-12
Session Date and Time:
09/12/2021, 10:30AM - 11:45AM EDT

Session title: Avelumab
Description: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
Abstract No: MP41-13
Session Date and Time:
09/12/2021, 10:30AM - 11:45AM PDT

Session title: Enzalutamide
Description: Enzalutamide in patients with localized prostate cancer undergoing active surveillance: ENACT
Abstract No: MP62-17
Session Date and Time:
09/13/2021, 10:30AM - 11:45AM PDT